Compare WIW & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIW | ASMB |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.4M | 512.1M |
| IPO Year | N/A | 2010 |
| Metric | WIW | ASMB |
|---|---|---|
| Price | $7.82 | $22.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $51.20 |
| AVG Volume (30 Days) | ★ 330.8K | 242.8K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.83 | $19.20 |
| 52 Week High | $8.87 | $39.65 |
| Indicator | WIW | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 53.16 |
| Support Level | N/A | $21.80 |
| Resistance Level | $8.00 | $23.83 |
| Average True Range (ATR) | 0.07 | 1.29 |
| MACD | -0.02 | 0.38 |
| Stochastic Oscillator | 15.71 | 68.84 |
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.